Early Reperfusion Therapy With Intravenous Thrombolysis for Recovery of VISION in Acute Central Retinal Artery Occlusion

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

422 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-10-10

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Non-arteritic, thromboembolic central retinal artery occlusion (CRAO) is an acute neurovascular-ophthalmological emergency which leads to severe and permanent vision loss; no evidence-based therapy does exist. Two recent meta-analyses indicate early intravenous thrombolysis to be beneficial in CRAO. Therefore, the REVISION randomized placebo-controlled interventional trial will investigate intravenous alteplase in CRAO as it is practiced in acute ischemic stroke, i.e. within 4.5 hours after symptom onset.

The REVISION observational study will evaluate retinal changes on optical coherence tomography (OCT) in patients within 12 hours of CRAO onset, and the REVISION substudy, which will be conducted adjunct to either the interventional or the observational study, will evaluate the value of the retrobulbar spot sign for prediction of outcome and treatment response.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

TENecteplase in Central Retinal Artery Occlusion Stuy (TenCRAOS)

NCT04526951

Central Retinal Artery Occlusion

COMPLETED PHASE3

Microneedle Intra-Arterial Injection for Retinal Artery Occlusion

NCT07151755

Central Retinal Artery Occlusion

RECRUITING NA

Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas

NCT02522897

Central Retinal Vein Occlusion With Macular Edema

UNKNOWN PHASE4

Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage

NCT00198497

Vitreous Hemorrhage Diabetic Retinopathy

COMPLETED PHASE3

Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement

NCT01783886

Macular Edema

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Non-arteritic, thromboembolic central retinal artery occlusion (CRAO) is an acute neurovascular-ophthalmological emergency which leads to severe and permanent vision loss in the affected eye in \~ 95% of cases. Despite a variety of widely practiced "conservative standard treatments", such as hemodilution, ocular massage, and paracentesis, there is no evidence-based therapy for non-arteritic CRAO. Animal models have proven a limited ischemic tolerance of the retina with irreversible damage occurring within only four hours after disruption of blood flow. This is why rapid reperfusion represents THE logical therapeutic approach. Two recent meta-analyses indicate early intravenous thrombolysis to be beneficial in CRAO. Therefore, the REVISION trial will investigate intravenous alteplase in CRAO as it is practiced in acute ischemic stroke, i.e. within 4.5 hours after symptom onset.

Sequential evaluation by optical coherence tomography (OCT) will visualize dynamic ischemic changes of the retina during and after CRAO. The REVISION observational study will enroll patients within 12 hours of symptom onset and aims at comparing late time window retinal findings to early ischemic changes found in patients of the randomized REVISION interventional trial. Ultimately, OCT may become the preferred tool when it comes to assess retinal tissue viability in patients with an unknown CRAO onset (e.g. wake-up CRAO), and CRAO patients who present in an extended time window beyond 4.5 hours.

The REVISION substudy, which will be conducted adjunct to either the interventional or the observational study, will evaluate the value of the retrobulbar spot sign for prediction of outcome and treatment response.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Retinal Artery Occlusion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Thrombolysis (interventional study)

Tenecteplase (0.25 mg per kg body weight as bolus; until trial protocol V04: Alteplase \[0.9 mg per kg body weight; 10% as bolus; remaining over one hour\] will be administered intravenously within 4.5 hours of symptom onset

Group Type ACTIVE_COMPARATOR

Tenecteplase (until trial protocol V04: Alteplase)

Intervention Type DRUG

Intravenous thrombolysis within 4.5 hours of symptom onset

Placebo (interventional study)

Placebo (0.25 mg per kg body weight as bolus; until trial protocol V04: 0.9 mg per kg body weight; 10% as bolus; remaining over one hour) will be administered intravenously within 4.5 hours of symptom onset

Group Type PLACEBO_COMPARATOR

Tenecteplase (until trial protocol V04: Alteplase)

Intervention Type DRUG

Intravenous thrombolysis within 4.5 hours of symptom onset

Observational study

The prospective REVISION observational study will enroll patients within 12 hours of symptom onset

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tenecteplase (until trial protocol V04: Alteplase)

Intravenous thrombolysis within 4.5 hours of symptom onset

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Acute non-arteritic CRAO (i.e. sudden, painless monocular vision loss) ≤ 12 hours after symptom onset confirmed by an experienced ophthalmologist through assessment of: BCVA, intraocular pressure, swinging flash light test (relative afferent pupil defect), slit-lamp biomicroscopy, fundoscopy, and OCT of the macula of both eyes\* (\*within the 4.5-hour time window: to be skipped if not feasible ≤ 10 minutes; beyond the 4.5-hour time window: mandatory)
* BCVA of LogMAR ≥ 1.3 in the affected eye (functional blindness according to WHO ICD-11)
* Reading must have been possible with the affected eye before CRAO (LogMAR ≤ 0.5)
* Neurological examination performed by an experienced stroke neurologist
* Brain imaging as per local standard for acute retinal ischemia/stroke assessment, either cranial computed tomography (CT) or cranial magnetic resonance imaging (MRI)

Exclusion Criteria

* Suspected giant cell arteritis
* Other-than-CRAO cause of acute visual loss (e.g., retinal detachment, vitreous hemorrhage, acute glaucoma, acute optic neuritis)
* BCVA of LogMAR \< 1.3 or rapidly improving vision in the affected eye
* Acute ischemic stroke with indication for on-label intravenous thrombolysis (IVT)
* Any co-existing or terminal disease with anticipated life expectancy of \< 3 months
* Prior participation in the REVISION trial

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No